News Search Year - Any - 2026 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2009 2008 Archive January 31, 2023 Deciphera Pharmaceuticals to Announce Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call and Webcast on February 7, 2023 Archive January 24, 2023 Deciphera Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares Archive January 24, 2023 Deciphera Pharmaceuticals Presents Results from ctDNA Analysis of INTRIGUE Phase 3 Clinical Study at the American Society of Clinical Oncology Plenary Series Session Archive January 19, 2023 Deciphera Pharmaceuticals Announces Pricing of Public Offering of Common Stock Archive January 18, 2023 Deciphera Pharmaceuticals Announces Proposed Public Offering of Common Stock Archive January 3, 2023 Deciphera Pharmaceuticals Announces Planned 2023 Corporate Milestones to Support Continued Evolution to Multi-Product Company Archive January 3, 2023 Deciphera Pharmaceuticals Announces Results from ctDNA Analysis from INTRIGUE Phase 3 Clinical Study Demonstrating Substantial Clinical Benefit of QINLOCK® in Second-Line GIST Patients with Mutations in KIT Exon 11 and 17/18 Only Archive January 3, 2023 Deciphera Pharmaceuticals, Inc. to Present at the 41st Annual J.P. Morgan Healthcare Conference Archive December 1, 2022 Deciphera Pharmaceuticals, Inc. to Present at the JMP Securities Hematology and Oncology Summit Archive November 8, 2022 Deciphera Pharmaceuticals, Inc. to Participate in Upcoming Investor Conferences
Archive January 31, 2023 Deciphera Pharmaceuticals to Announce Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call and Webcast on February 7, 2023
Archive January 24, 2023 Deciphera Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
Archive January 24, 2023 Deciphera Pharmaceuticals Presents Results from ctDNA Analysis of INTRIGUE Phase 3 Clinical Study at the American Society of Clinical Oncology Plenary Series Session
Archive January 19, 2023 Deciphera Pharmaceuticals Announces Pricing of Public Offering of Common Stock
Archive January 18, 2023 Deciphera Pharmaceuticals Announces Proposed Public Offering of Common Stock
Archive January 3, 2023 Deciphera Pharmaceuticals Announces Planned 2023 Corporate Milestones to Support Continued Evolution to Multi-Product Company
Archive January 3, 2023 Deciphera Pharmaceuticals Announces Results from ctDNA Analysis from INTRIGUE Phase 3 Clinical Study Demonstrating Substantial Clinical Benefit of QINLOCK® in Second-Line GIST Patients with Mutations in KIT Exon 11 and 17/18 Only
Archive January 3, 2023 Deciphera Pharmaceuticals, Inc. to Present at the 41st Annual J.P. Morgan Healthcare Conference
Archive December 1, 2022 Deciphera Pharmaceuticals, Inc. to Present at the JMP Securities Hematology and Oncology Summit
Archive November 8, 2022 Deciphera Pharmaceuticals, Inc. to Participate in Upcoming Investor Conferences
